Resverlogix Corp. · TSX:RVX
Resverlogix — CTAD 2021
12 slides from Resverlogix's conference presentation, 2021
Slide 1: The Epigenetic Modulator Apabetalone Decreases Neuroinflammation in Blood Brain Barrier Cell Models and LPS-Treated Mice
TSX: RVX The Epigenetic Modulator Apabetalone Decreases Neuroinflammation in Blood Brain Barrier Cell Models and LPS-Treated Mice Sylwia Wasiak, PhD Research Scientist Resverlogix Corp. Disclosures: This work was financially supported by Resverlogix Corp. I have received a salary and stock options f
Slide 2: Epigenetics
Epigenetics The epigenetic code refers to secondary modifications to chromatin components that regulate transcriptional activity Addition, removal or recognition of these modifications is done by proteins called writers, erasers and readers Acetylation of histone lysine residues by writers marks act
Slide 3: Apabetalone (RVX-208) Is a Small Molecule Inhibitor that Competitively Inhibits BET Bromodomains
Apabetalone (RVX-208) Is a Small Molecule Inhibitor that Competitively Inhibits BET Bromodomains BET proteins are part of a superfamily of proteins Each BET protein contains two bromodomains (BD) 1 74-185 345-457 632-710 801 BRD2 BD1 BD2 ET 1 34-145 307-419 562-640 726 BRD3 BD1 BD2 ET 1 58-159 349-4
Slide 4: Apabetalone in Human Clinical Trials
Apabetalone in Human Clinical Trials • Apabetalone/RVX-208/RVX000222 (2-(4-(2-hydroxyethoxy)-3,5-dimethylphenyl)-5,7-dimethoxyquinazolin-4(3H)-one) was discovered in 2006. • Tested in multiple phase 2 trials in CVD patients (endpoints: HDL, ApoA-I elevation) • Phase 3 cardiovascular event-driven tri
Slide 5: Endothelial Dysfunction and Monocyte Infiltration Contribute to Neuroinflammation
Endothelial Dysfunction and Monocyte Infiltration Contribute to Neuroinflammation • Peripheral inflammation associated with chronic disease causes brain endothelial cells to express proinflammatory molecules and to lose their barrier properties, allowing for monocyte infiltration into the brain. • E
Slide 6: Apabetalone Counters Cytokine Expression in Brain Endothelial Cells
Apabetalone Counters Cytokine Expression in Brain Endothelial Cells Endothelial Monolayer In vivo In vitro Polarized Cytokine Secretion Permeability TNFα+IFNγ Stimulation (4h) of hCMEC/D3 cells Gene Expression Luminal Secretion Basolateral Secretion Vehicle Apabetalone Vehicle Apabetalone Vehicle Ap
Slide 7: Apabetalone Reduces Monocyte Chemoattraction
Apabetalone Reduces Monocyte Chemoattraction In vivo In vitro Expression of chemokine receptors CCR1In Vitro CCR2 CCR5 Cell Migration Assay Monocyte THP-1 Monocyte MCP-1 RANTES mRNA Ratio Chemoattraction to MCP-1 or RANTES Protein Ratio Apabetalone treatment reduced chemokine receptor expression and
Slide 8: Apabetalone Reduces Endothelial Adhesion Molecule Expression and Monocyte Adhesion to Brain Endothelial Cells
Apabetalone Reduces Endothelial Adhesion Molecule Expression and Monocyte Adhesion to Brain Endothelial Cells In vivo In vitro THP-1 – hCMEC/D3 EndothelialAdhesion AdhesionAssay Molecule Expression Phase contrast: THP-1 Monocyte VCAM1 mRNA VCAM1 Protein Adhesion to hCMEC/D3 Quantification: Apabetalo
Slide 9: Apabetalone Reduces the Expression of Monocyte Adhesion Receptors and their Adhesion to Endothelial Cells
Apabetalone Reduces the Expression of Monocyte Adhesion Receptors and their Adhesion to Endothelial Cells In vivo In vitro THP-1 – Integrin hCMEC/D3 Expression AdhesioninAssay THP-1 Cells Fluorescence: ITGA4 ITGAL THP-1 Monocyte Adhesion mRNA Ratio to hCMEC/D3 Quantification: Protein Ratio Apabetalo
Slide 10: Apabetalone Reduces the Expression of Endothelial and Leukocyte Inflammation Markers in the Mouse Brain
Apabetalone Reduces the Expression of Endothelial and Leukocyte Inflammation Markers in the Mouse Brain Gene Expression in the Mouse Brain Brain Pharmacokinetics Tissue Apabetalone Brain 2.4 µM Plasma 32 µM Brain : Plasma Ratio 0.07 Peripheral activity of apabetalone reduces endothelial activation i
Slide 11: Pro-Inflammatory Monocyte Hyper-Activation Is Sensitive to BET Inhibition: Summary
Pro-Inflammatory Monocyte Hyper-Activation Is Sensitive to BET Inhibition: Summary • Monocytes from DM2+CVD patients exhibit pro-inflammatory hyper-activation at baseline. • Monocytes from DM2+CVD patients are hyper-responsive to IFNγ upon ex vivo stimulation. • This pro-inflammatory hyper-activatio
Slide 12: Thank you for your attention!
Select Publications: • Wasiak 2020 BET protein inhibitor apabetalone (RVX-208) suppresses pro-inflammatory hyper-activation of monocytes from patients with Acknowledgements cardiovascular disease and type 2 diabetes. Clinical Epigenetics. • Wasiak 2020 Epigenetic Modulation by Apabetalone Counters C